Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study Report Prakash Satwani, Harland Sather, Fevzi Ozkaynak, Nyla A. Heerema, Kirk R. Schultz, Jean Sanders, John Kersey, Virginia Davenport, Michael Trigg, Mitchell S. Cairo Biology of Blood and Marrow Transplantation Volume 13, Issue 2, Pages 218-227 (February 2007) DOI: 10.1016/j.bbmt.2006.09.013 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Probability of 5-year event-free survival (EFS) by Kaplan-Meier estimates in children with ultra-high-risk features of acute lymphoblastic leukemia in first complete remission treated with allogeneic bone marrow transplantation in the Children’s Cancer Group 1921 study. Biology of Blood and Marrow Transplantation 2007 13, 218-227DOI: (10.1016/j.bbmt.2006.09.013) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Probability of 5-year event-free survival (EFS) by Kaplan-Meier estimates in children with Philadelphia chromosome-positive t(9;22) acute lymphoblastic leukemia in first complete remission treated with allogeneic bone marrow transplantation in the Children’s Cancer Group 1921 study. Biology of Blood and Marrow Transplantation 2007 13, 218-227DOI: (10.1016/j.bbmt.2006.09.013) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions